Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

Single-cell immune profiling reveals markers of emergency myelopoiesis that distinguish severe from mild respiratory syncytial virus disease in infants.

Zivanovic N. et al, (2023), Clin Transl Med, 13

Salmonella Vaccine Study in Oxford (SALVO) trial: protocol for an observer-participant blind randomised placebo-controlled trial of the iNTS-GMMA vaccine within a European cohort.

Hanumunthadu B. et al, (2023), BMJ Open, 13

Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial.

Ramasamy MN. et al, (2021), Lancet, 396, 1979 - 1993

Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002).

Flaxman A. et al, (2021), Lancet, 398, 981 - 990

Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial.

Frater J. et al, (2021), Lancet HIV, 8, e474 - e485

Presumed Risk Factors and Biomarkers for Severe Respiratory Syncytial Virus Disease and Related Sequelae: Protocol for an Observational Multicenter, Case-Control Study From the Respiratory Syncytial Virus Consortium in Europe (RESCEU).

Jefferies K. et al, (2020), J Infect Dis, 222, S658 - S665

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial (vol 396, pg 467, 2020)

Folegatti PM. et al, (2020), LANCET, 396, 466 - 466

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial.

Folegatti PM. et al, (2020), Lancet, 396, 467 - 478

Respiratory Syncytial Virus Consortium in Europe (RESCEU) Birth Cohort Study: Defining the Burden of Infant Respiratory Syncytial Virus Disease in Europe.

Wildenbeest JG. et al, (2020), J Infect Dis

Immunogenicity and Reactogenicity of a Reduced Schedule of a 4-component Capsular Group B Meningococcal Vaccine: A Randomized Controlled Trial in Infants.

Valente Pinto M. et al, (2020), 7

Low Sensitivity of BinaxNOW RSV in Infants.

Zuurbier RP. et al, (2020), J Infect Dis

Persistent circulation of vaccine serotypes and serotype replacement after five years of UK infant immunisation with PCV13.

Kandasamy R. et al, (2019), J Infect Dis

Meningococcal carriage in adolescents in the United Kingdom to inform timing of an adolescent vaccination strategy.

Jeppesen CA. et al, (2015), J Infect, 71, 43 - 52

Persistence of specific bactericidal antibodies at 5 years of age after vaccination against serogroup B meningococcus in infancy and at 40 months.

McQuaid F. et al, (2015), CMAJ, 187, E215 - E223

A cross-sectional observational study of pneumococcal carriage in children, their parents, and older adults following the introduction of the 7-valent pneumococcal conjugate vaccine.

Hamaluba M. et al, (2015), Medicine (Baltimore), 94

Persistence of bactericidal antibodies to 5 years of age after immunization with serogroup B meningococcal vaccines at 6, 8, 12 and 40 months of age.

McQuaid F. et al, (2014), Pediatr Infect Dis J, 33, 760 - 766

Persistence of bactericidal antibodies following early infant vaccination with a serogroup B meningococcal vaccine and immunogenicity of a preschool booster dose.

Snape MD. et al, (2013), CMAJ, 185, E715 - E724

Bactericidal antibody persistence 2 years after immunization with 2 investigational serogroup B meningococcal vaccines at 6, 8 and 12 months and immunogenicity of preschool booster doses: a follow-on study to a randomized clinical trial.

Snape MD. et al, (2013), Pediatr Infect Dis J, 32, 1116 - 1121

Bactericidal antibody persistence 2 years after immunization with 2 investigational serogroup B meningococcal vaccines at 6, 8 and 12 months and immunogenicity of preschool booster doses: A follow-on study to a randomized clinical trial

Snape MD. et al, (2013), Pediatric Infectious Disease Journal, 32, 1116 - 1121

Maintenance of immune response throughout childhood following serogroup C meningococcal conjugate vaccination in early childhood.

Khatami A. et al, (2011), Clin Vaccine Immunol, 18, 2038 - 2042

Include forthcoming?